{
    "id": 19620,
    "fullName": "CDH1 R63*",
    "impact": "nonsense",
    "proteinEffect": "loss of function - predicted",
    "geneVariantDescriptions": [
        {
            "description": "CDH1 R63* results in a premature truncation of the Cdh1 protein at amino acid 63 of 882 (UniProt.org). Due to the loss of all known functional domains (UniProt.org), R63* is predicted to lead to a loss of Cdh1 function.",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 999,
        "geneSymbol": "CDH1",
        "terms": [
            "CDH1",
            "Arc-1",
            "BCDS1",
            "CD324",
            "CDHE",
            "ECAD",
            "LCAM",
            "UVO"
        ]
    },
    "variant": "R63*",
    "createDate": "03/14/2016",
    "updateDate": "09/06/2018",
    "referenceTranscriptCoordinates": {
        "id": 121960,
        "transcript": "NM_004360",
        "gDna": "chr16:g.68801693C>T",
        "cDna": "c.187C>T",
        "protein": "p.R63*",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 5027,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, treatment with the combination of Tykerb (lapatinib) and Xeloda (capecitabine) resulted in prolonged response and reduction in liver metastasis in a metastatic breast cancer patient harboring ERBB2 L869Q and CDH1 R63* mutations (PMID: 26487584).",
            "molecularProfile": {
                "id": 20031,
                "profileName": "CDH1 R63* ERBB2 L869Q"
            },
            "therapy": {
                "id": 1399,
                "therapyName": "Capecitabine + Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4844,
                    "pubMedId": 26487584,
                    "title": "A clinical case of invasive lobular breast carcinoma with ERBB2 and CDH1 mutations presenting a dramatic response to anti-HER2-directed therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26487584"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 20029,
            "profileName": "CDH1 R63*",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 20031,
            "profileName": "CDH1 R63* ERBB2 L869Q",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 121960,
            "transcript": "NM_004360",
            "gDna": "chr16:g.68801693C>T",
            "cDna": "c.187C>T",
            "protein": "p.R63*",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 121961,
            "transcript": "NM_001317184",
            "gDna": "chr16:g.68801693C>T",
            "cDna": "c.187C>T",
            "protein": "p.R63*",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}